LG Chem Life Sciences Innovation Center and LabCentral Announce the 2021 Golden Ticket Winner – Thymmune Therapeutics, Inc.

LG Chem Life Sciences Innovation Center and LabCentral Announce the 2021 Golden Ticket Winner – Thymmune Therapeutics, Inc.




LG Chem Life Sciences Innovation Center and LabCentral Announce the 2021 Golden Ticket Winner – Thymmune Therapeutics, Inc.

CAMBRIDGE, Mass.–(BUSINESS WIRE)–#CellTherapy–Today, LG Chem Life Sciences Innovation Center announces that it has selected Thymmune Therapeutics as the winner of their 2021 Golden Ticket Program. LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups located in the heart of Kendall Square in Cambridge, MA. The Golden Ticket will provide Thymmune Therapeutics with a voucher for one year of prepaid rent for a reserved bench space for one scientist, including benefits of shared infrastructure and services.


As a LabCentral sponsor, LG Chem Life Sciences Innovation Center can select a qualifying startup company each year to take up residence in LabCentral’s Kendall Square facility through use of the Golden Ticket. LG Chem’s Golden Ticket Program is designed to assist high-potential and innovative early-stage life science and biotech companies.

“The Golden Ticket is an effective way to establish a close connection with innovation and new companies that are working in the Cambridge biotech ecosystem,” said Alex Gaither, Vice President, Translational Medicine at the LG Chem Life Sciences Innovation Center. “We spent several months connecting with numerous companies across Cambridge to finally decide on and recognize Thymmune. The novel approach Thymmune is taking in scalable thymic cells is quite unique and we are excited to see the progress of their platform over the next year.”

Thymmune Therapeutics is a preclinical company focused on developing thymic cell therapies. “We are honored by this wonderful recognition of our work by LG Chem as it reaffirms our mission to serve patients with unmet need across immunology utilizing our thymic engineering platform and cell therapies,” said Stan Wang, CEO and Founder of Thymmune Therapeutics. “The Golden Ticket catalyzes our innovative R&D efforts and extends our resources for the important science involved in moving our work to the clinic within the heart of the Boston/Cambridge biotech ecosystem.”

About LG Chem Life Sciences

LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue global collaboration encompassing from asset-centric to strategic investment and collaboration.

About Thymmune Therapeutics

Thymmune Therapeutics is a preclinical biotechnology company based in Cambridge, MA applying proprietary insights in thymic engineering to develop and commercialize immune cell therapy products addressing significant opportunities with unmet clinical need across immunology. Building on work from leading labs, Thymmune has strong IP positioning and is backed by early investors and founders of successful high-profile biotechnology companies.

Contacts

LG Chem Life Sciences Innovation Center
General Inquiries: contact.cbl@lgchem.com
Partners: partners.cbl@lgchem.com
Media (Jiin Chung): media.cbl@lgchem.com

Thymmune Therapeutics
General Inquiries: info@thymmune.com

LabCentral
Lindsay Crockett: lcrockett@labcentral.org